Fortis Healthcare has disclosed that its material subsidiary, Agilus Diagnostics Limited, approved an intra-group restructuring scheme on August 5, 2026. The Board of Directors of Agilus Diagnostics concluded its meeting at 04:30 PM with the approval to merge two wholly owned subsidiaries—Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited—into Agilus Diagnostics Limited via a Scheme of Arrangement. This consolidation aims to streamline operations within the group’s diagnostics vertical, requiring no financial consideration as it is an internal restructuring of wholly owned entities.

Merger Details

The approved Scheme involves the amalgamation of the following entities:

As this is an intra-group merger involving wholly owned subsidiaries, no consideration will be payable pursuant to the Scheme. The transaction is designed to simplify the corporate structure under the Agilus Diagnostics umbrella.

Regulatory Approvals Required

The Scheme remains subject to several regulatory and statutory approvals before implementation. These include:

• Approval from the jurisdictional National Company Law Tribunals (NCLTs).
• Consent from any other relevant authorities as may be required.
• Approval from the members and creditors of the involved companies.

Disclosure Compliance

Fortis Healthcare made this disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was issued to the National Stock Exchange of India Ltd. and BSE Limited on August 5, 2026, following the board meeting held on the same date.

Fortis Healthcare Limited will host a conference call on Friday, August 07, 2026, at 11:00 am IST to discuss its unaudited financial results for the quarter ended June 30, 2026. This disclosure ensures transparency for investors and analysts regarding the company's performance in Q1FY27. The announcement was made on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Satyendra Chauhan, Company Secretary & Compliance Officer, signed the intimation submitted to both the National Stock Exchange of India Ltd. and BSE Limited. The filing confirms that no Unpublished Price Sensitive Information (UPSI) will be shared during the proceedings, adhering to regulatory standards for fair disclosure.

Conference Call Details

The session is structured as a virtual group call, accessible to investors and analysts from India and international markets. Management will address queries regarding the Q1FY27 performance, offering insights into revenue streams, patient footfall, and margin dynamics without revealing any price-sensitive data prior to the official release. Participants can join via the provided dial-in numbers or through the Express Join link using DiamondPass™ to avoid operator wait times.

For those unable to attend live, a replay of the conference call will be available from August 07, 2026, to August 14, 2026. The replay can be accessed by calling +91 22 7194 5757 and entering the playback ID: 27619.

What to Expect

While specific financial figures were not disclosed in this scheduling notice, the timing of the call indicates that Fortis Healthcare has completed its internal review of Q1FY27 results. Investors should monitor the subsequent exchange filings for detailed metrics on net profit, revenue from operations, and EBITDA margins. The focus during the call is expected to be on explaining variances from previous periods and outlining strategic initiatives for the remainder of FY27.